South African Medical Research Council

2015/16 Annual Performance Plan, Budget and

2015/16 – 2019/20 Strategic Plan

Briefing to the Portfolio Committee on Health

2015

Scope of Presentation

• SAMRC Board & Mission of the SAMRC: Mike

Sathekge

• SAMRC financial report: Nick Buick

• SAMRC Employment Equity Profile: Mbulelo

Bikwani

• SAMRC scientific progress, performance,

governance and strategic direction: Glenda

Gray

• SAMRC PUDAC: Chesa Chauke

• SAMRC ACT: Nkosinathi Bhuka

VISIONBuilding a healthy nation through

research and innovation

MISSIONTo improve the nation’s health and quality of life by conducting and

funding relevant and responsive health research, development,

innovation and research translation

STRATEGIC GOALS OF THE SAMRC

• Administer Health Research effectively &

efficiently (20: 40: 40 split of funding )

• Lead the generation of new knowledge

• Support innovation and technology

development to improve health

• Build capacity for the long term sustainability of

the country’s health research

Prof Mike Machaba Sathekge

Chairperson

Prof Sathekge is Chief Specialist and head of department of Nuclear Medicine at the University of Pretoria / Steve Biko Academic Hospital. He has had a wide range of academic research and professional roles, which have resulted in many national and international publications.

Prof Zodwa Dlamini

Vice-Chairperson

Professor Zodwa Dlamini is a Professor of Functional Genomics and Molecular Medicine and the Deputy Executive Dean at UNISA Science Campus. She also represents the Department of Health in the DST Scientific Advisory Board on the National Preclinical Drug Development Platform. Professor Dlamini also currently holds an appointment as an Honorary Research Fellow and Professor for the University of Bristol, School of Medical Sciences, United Kingdom. Her research interests is in functional genomics which include the “omics” technologies (transcriptomics, genomics and proteomics) including the use of bioinformatics to provide unprecedented possibilities to identify the underlying molecular basis of many common diseases including cancer, HIV/AIDS and diseases of lifestyle

Dr Francesca Conradie

Dr Conradie is a Clinical Investigator at the University of Witwatersrand. Her research career started in 2000 at the Clinical HIV Research Unit of the University of Witwatersrand as an investigator in HIV related clinical trials both randomised clinical trials and investigator initiated operational work. In 2009 her focus changed to Drug Resistant TB and its overlap in HIV infection. She is the President of the Southern African HIV Clinicians Society and a member of the Human Research Ethics Committee of the University of the Witwatersrand.

Prof Charles Feldman

Prof Feldman started his career as an intern at Johannesburg Hospital in 1976. His experiences include Medical Officer in the Defence Force, Director of Pulmonology and Intensive Care Unit, and Research Fellow and Honorary Senior Visitor Colleague at the Royal Brampton Hospital in the UK. Currently, Prof Feldman is Professor of Pulmonology and Chief Physician in the Pulmonology Division of Carlotte Maxeke Johannesburg Academic Hospital and University of the Witwatersrand.

SAMRC Board

1 November 2013 to 31 October 2016

Dr Sibongile Gumbi

Dr. Gumbi is currently Group Executive Biotechnology at the Technology Innovation Agency (TIA) where she is responsible for investing in local biotechnology opportunities and managing a portfolio of investments in this area. She is also an entrepreneur having established Smart Innovation in 2007 and managed several start-up enterprises in the pharmaceutical area. Dr. Gumbi’s previous positions include IKS manager at the MRC and Group Manager: R&D Outcomes at the CSIR. She has a PhD in Pharmacology, obtained from UCT. She is currently studying for a MBA through IMD, Switzerland.

Dr Patricia Hanekom

Dr Hanekom held the position of Accounting Officer in the Gauteng Provincial Government for 12 years and has extensive experience, skills and knowledge with respect to governance and accountability. She has been appointed as a member of the Ministerial Advisory Task Team for the establishment of the National School of Government and serves on a number of Boards and Audit Committees.

Dr Zilungile Kwitshana

Dr Kwitshana is a Lecturer and Medical Scientist at the University of KwaZulu-Natal. Her research focus is the Immunological and Nutritional Impact of co-infection with HIV and Neglected Tropical Diseases (Helminthiasis). The other aspect of her research focuses on revitalising capacity in medical parasitology for national control of neglected tropical diseases. She is an external reviewer for a number of leading scientific journals and serves on a number of Boards.

Prof. Khaya Mfenyana

Prof Kaya Mfenyana is Head: Office of the Vice Chancellor and Outgoing Executive Dean of the Medical School, Walter Sisulu University. His research focus is Primary Health Care and Medical Education, especially Community-Based Learning and Service-Learning. He serves on a number of Boards and has also been appointed as a member of the Joint Technical Task Team to advise on processes for separating the Medunsa Campus from the University of Limpopo and establishing a new University incorporating the Medunsa Campus.

Prof Yusuf Osman

Prof Osman is Dean/Manager: Dental Faculty/ Oral Health Centres at the University of the Western Cape. He has a keen interest in advances in dental materials and how this impacts on managing the Burden of Disease as regards Oral Health. He is a sought after national and internal speaker and serves on a number of advisory panels and Committees.

Adv. Josephine Ralefatane

Advocate Ralefatane has attained her B. Proc and LLB degree and is an admitted Advocate of the Supreme Court of South Africa. She has extensive experience in law, serving as a Legal Advisor in the private and public sectors as well as acting as arbitrator, conciliator and mediator. She currently serves on various Boards and Committees.

Prof Keitshepile Setswe

Prof Setswe is currently Professor of Public Health and the founding Head of the School of Health Sciences at Monash University South Africa campus. His research interests are in the behavioural and social aspects of HIV/AIDS/STI/TB, AIDS and health policy, epidemiology and general public health issues. He returns to the Human Sciences Research Council (HSRC) as Deputy Executive Director for the HIV/AIDS/STI/TB (HAST) research programme on 1 December 2013. He was Chief Research Specialist and later Research Director in the same research programme from 2006-2010 and has previously served as Regional Director and acting Director for Social Aspects of HIV/AIDS Research Alliance (SAHARA) from 2006 to 2010.

Prof Andrew Walubo

Prof Walubo is Head of the Department of Pharmacology, University of the Free State, and Chief Clinical Pharmacologist, Universitas Academic Hospital. His research focus is Clinical Pharmacology, Drug Metabolism & Transport, Quality Practices (GLP and GCP), Immunopharmacology and Traditional Medicines. He has published several scientific articles in peer reviewed journals and presented many abstracts at national and international conferences. He serves on a number of health related committees and boards, including the Medicines Control Council and the senate of the College of Medicines of South Africa.

Prof Elizabeth Anne Bukusi

Prof Elizabeth Anne Bukusi is the Deputy Director, Research and Training at the Kenya Medical Research Institute (KEMRI) and Chief Research Officer, KEMRI Centre for Microbiology Research. She is an Honorary Lecturer, Department of Obstetrics and Gynaecology, University of Nairobi, Associate Research Professor, University of Washington and Honorary Lecturer, Department of Obstetrics and Gynaecology, Aga Khan University. Her primary research focuses on sexually transmitted infections, reproductive health and HIV prevention, care and treatment. She also has an interest in ethics and the development of systems and structures for regulation of research in the institute and the country. In addition to the committees she chairs at KEMRI, Prof Bukusi serves on a number of scientific committees including the Kenya National HIV prevention task force and the WHO Department of Reproductive Health Scientific Technical Advisory Board (STAG).

Prof. Khaya Mfenyana

Prof Kaya Mfenyana is Head: Office of the Vice Chancellor and Outgoing Executive Dean of the Medical School, Walter Sisulu University. His research focus is Primary Health Care and Medical Education, especially Community-Based Learning and Service-Learning. He serves on a number of Boards and has also been appointed as a member of the Joint Technical Task Team to advise on processes for separating the Medunsa Campus from the University of Limpopo and establishing a new University incorporating the Medunsa Campus.

Prof Pindile Mntla

Prof Mntla is the Head of the Department of Cardiology at the University of Limpopo: Medunsa Faculty of Health Sciences and Dr George Mukhari Academic Hospital. His research focus includes Pericarditis, Peri-Partum Cardiomyopathy, systemic Hypertension, especially in the black population, Rheumatic Fever and Valvular Heart Diseases, especially in pregnancy. He serves on a number of esteemed Committees and Boards.

Prof Kebogile Mokwena

Prof Kebogile Mokwena is Head of Department of Public Health, Medunsa Campus. Her research interests include culture sensitive health promotion, public health training programs, asthma, non communicable diseases and drug abuse. She is a reviewer of manuscripts for several research journals and serves in a number of Boards

Prof Keymanthri Moodley

Prof Moodley completed her undergraduate medical training in 1988, and in 2004, she was awarded her doctorate in Bioethics. She is Associate Professor at the Bioethics Unit – Tygerberg Division and works as an investigator on clinical trials. For the past seven years, Professor Moodley has also provided Good Clinical Practice Training at the faculty. She has recently been appointed to the National Health Research Ethics Council.

• We are administering health

research efficiently and

effectively!

• Clean Audits & Lean Support

• Great Science

SA’s Burden of Disease – MRC guide

Cause of death Deaths %

HIV/AIDS 180,870 29.4

Hypertensive heart disease 39,272 6.4

Lower respiratory infections 38,576 6.3

Cerebrovascular disease 37,913 6.2

Tuberculosis 37,519 6.1

Diarrhoeal diseases 26,564 4.3

Ischaemic heart disease 24,510 4.0

Interpersonal violence 20,155 3.3

Road injuries 18,166 3.0

Diabetes mellitus 13,667 2.2

COPD 11,458 1.9

Nephritis/nephrosis 9,130 1.5

Top 12 causes 457,800 74.3

Total 615,788 100.0

SA MRC is committed to addressing the burden of disease that impacts health

FINANCE : Nick Buick

Summary of Income for MTEF period

12

ESTIMATED INCOME OVER MTEF PERIOD

DESCRIPTION 2014/15 % Incr 2015/16 % Incr 2016/17 % Incr 2017/18

BASELINE FUNDING

Permanent Baseline Allocation 303,799,421 56% 473,892,000 7% 507,590,000 1% 514,961,000

Economic Competitive & Support Package 100,000,000 50% 150,000,000 0% 150,000,000 -33% 100,000,000

Total Allocation from National Treasury 446,331,000 40% 623,892,000 5% 657,590,000 -6% 614,961,000

Other Income

Investment Income 20,000,000 25,000,000 26,000,000 27,000,000

Sundry Income 11,430,000 14,201,000 11,074,000 11,855,000

Total Baseline Allocation 31,430,000 25% 39,201,000 -5% 37,074,000 5% 38,855,000

Total Estimated Baseline Income 477,761,000 39% 663,093,000 5% 694,664,000 -6% 653,816,000

CONTRACT FUNDING

Research Contract Funding 306,839,000 356,981,000 348,080,000 357,224,000

TOTAL ESTIMATED FUNDING 784,600,000 30% 1,020,074,000 2% 1,042,744,000 -3% 1,011,040,000

EXPENDITURE PER STRATEGIC PROGRAMME

13

Audited

Outcome

Audited

Outcome

Audited

Outcome

Revised

estimate

Average

growth

rate

(%)

Expen-

diture/

total:

Average

(%) Medium-term estimate

Average

growth

rate

(%)

Expen-

diture/

total:

Average

(%)

R thousand 2011/12 2012/13 2013/14 2014/15 2015/16 2016/17 2017/18 2014/15 - 2017/18

Administration 143,962 156,463 175,327 161,793 4.0% 23.9% 171,666 187,978 181,215 3.9% 18.1%

Core research 423,423 406,011 471,099 549,329 9.1% 68.6% 597,911 655,893 640,139 5.2% 62.8%

Innovation and technology 4,951 7,752 59,015 83,247 156.2% 5.1% 215,296 161,612 151,242 22.0% 15.4%

Capacity development 8,207 6,726 22,311 34,231 61.0% 2.4% 35,201 37,261 38,444 3.9% 3.7%

- – – – – – – – – – – –

Total expense 580,543 576,952 727,752 828,600 12.6% 100.0% 1,020,074 1,042,744 1,011,040 6.9% 100.0%

2011/12 - 2014/15

Overview of Total MRC Budget

14

NATIONAL TREASURY FUNDING OVER MTEF PERIOD

DESCRIPTION 2014/15 % Incr 2015/16 % Incr 2016/17 % Incr 2017/18

Income 446,331,000 40% 623,892,000 5% 657,590,000 -6% 614,961,000

Expenditure 490,331,000 27% 623,892,000 5% 657,590,000 -6% 614,961,000

Projected Surplus / deficit -44,000,000 0 0 0

PROJECTED OTHER RESEARCH FUNDING OVER MTEF

DESCRIPTION 2014/15 % Incr 2015/16 % Incr 2016/17 % Incr 2017/18

Contract Research Income 338,269,000 17% 396,182,000 -3% 385,154,000 3% 396,079,000

Contract Research Expenditures 338,269,000 17% 396,182,000 -3% 385,154,000 3% 396,079,000

Projected Surplus / deficit 0 0 0 0

TOTAL PROJECTED FUNDING OVER MTEF

DESCRIPTION 2014/15 % Incr 2015/16 % Incr 2016/17 % Incr 2017/18

Income 784,600,000 30% 1,020,074,000 2% 1,042,744,000 -3% 1,011,040,000

Expenditure 828,600,000 23% 1,020,074,000 2% 1,042,744,000 -3% 1,011,040,000

Projected Surplus / deficit -44,000,000 0 0 0

Financial Summary• Growth of SAMRC budget of 30% for 2015/16 to R1b.

• Over the MTEF MRC will leverage international funding at a

ratio of at least 1:1

• R30m p.a. from Bill & Milinda Gates Foundation,

Newton Fund & Wellcome Trust

• R40m p.a. from National Institutes of Health for 3 years

• Funding towards Administration will also reduce from

23.9% to 18.1% due to improved efficiencies

• A concern is the reduction in Government funding in

2017/18 when the Economic Competitiveness Funding

allocation reduces by R50m

15

TRANSFORMATION – Mbulelo Bikwani

EE Profile 1 Jan – 31 March 2015 compared to 1 Oct -31 Dec 2014

17

Female Male Foreign Nationals

OCC

LEVEL A C I W A C I W Female Male TOTAL

QUARTE

R Q4 Q3 Q4 Q3

Q

4 Q3 Q4 Q3 Q4 Q3 Q4 Q3 Q4 Q3 Q4 Q3 Q4 Q3 Q4 Q3 Q4 Q3

TOP MAN 2 2 1 1 3 3

SENIOR

MAN 3 3 5 5 3 3 14 14 3 3 3 3 33 14 14 2 2 3 2 52 52

PROFES

QUALIFIE

D &

SPECIALI

STS 23 22 23 22 37 38 31 34 7 6 8 8 7 7 6 7 9 8 6 4 157 156

SKILLED

TECHNIC

AL &

ACADEMI

CALLY

QUALIF. 87 92 51 51 40 39 13 12 15 18 20 20 11 11 3 3 4 4 1 2 245 252

SEMI-

SKILLED

&

DISCRET.

DECISIO

N

MAKING 39 38 12 12 10 10 4 4 20 21 7 7 2 2 0 0 0 0 0 0 94 94

UNSKILL

ED AND

DEFINED

DECISIO

N

MAKING 7 8 6 6 0 0 0 0 22 22 6 6 4 4 1 1 0 0 0 0 46 47

Total 159 163 97 96 90 90 64 64 68 71 44 44 27 27 23 25 15 14 10 8 597 604

18

The Employment Equity profile of the organization from 1 Jan – 31 March 2015 compared to 1 Oct -31 Dec

2014, is reflected in the table above:

• Employee headcount was 597 in Q4 and 604 in Q3.

• The profile is made up of: Q4:40.87% and Q3: 41.23% African; Q4 23.79% and Q3 23.34% Coloured;

Q4 20.10% and Q3 19.87% Indian and Q4 15.24% and Q3 15.56% White. The gender profile is Q4

71.19% and Q3 71.03% female and Q4 28.81% and Q3 28.97% male.

• EMC has now approved a plan and composition of the widely representative transformation forum and

the next step is to nominate and appoint transformation forum members as a monitoring body for

Transformation.

• The forum will be responsible for producing the EE Plan which will deal with matters of:

• Organizational culture and Diversity.

• Talent management including interventions to build a healthy pipeline of the under-represented

scientists.

• Age/retirement management leading to succession planning. In Our plans we have identified that

in the next 8 years we will have 11 Unit Directors/Executives that would either have retired or

have their contracts ended. This gives the organization an opportunity to transform the Executive

and Senior leadership levels.

• Monitoring and implementation of transformation interventions within the MRC.

SCIENTIFIC REPORT – Glenda Gray

SAMRC is a National Resource

• Lead research at a national level

• International stature: HIRO

• Both intramurally and in the extramural space there is scientific

depth

• Have access both nationally & internationally

• Driver national priorities of medical research

• Create the ideas to drive innovation in top 10 causes of mortality

• National TB survey

• SADHS

• Newton Fund

• Grand Challenges SA

• Brain Initiative

2014/15 Annual Performance Plan

21

2014/15 Annual Performance Plan - Projected 4th Quarterly Report

Strategic GOAL Strategic Objective

Ind

icato

r No

.

Programme Performance Indicator

Reporting period: 2014/15

Performance Target

Frequ

ency

1st Q Target

Actu

al

2nd

Q Target

Actu

al

3rd Q

Target

Actu

al

4th Q

Target

Pro

jected A

ctual

Reporting period: 2014/15

Projected Performance

Administer health research effectively and efficiently in South

Africa

To ensure good governance, effective administration and compliance with

government regulations

1.1Compliance with legislative prescripts, reflected in audit findings relating to the processes and systems of the MRC

Clean AnnualAvailable

after Audit

Available after Audit

1.2% of the 2014/15 government allocated MRC budget spent on administration

30% Annual 20%20%

Lead the generation of new knowledge and facilitate its

translation into policies and practices to improve health

To produce and disseminate new scientific findings and knowledge on health

2.1*Number of peer reviewed articles with an MRC-affiliated author that are published in ISI journals during the reporting period

400 Quarterly 105 130 110 109 80 129 105 105 473

2.2*Number of peer reviewed articles published in ISI journals with acknowledgement of MRC support during the reporting period

100 Quarterly 25 13 25 7 25 9 25 69 98

To promote scientific excellence and the reputation of South African health research

2.3*Number of peer reviewed articles with an MRC-affiliated author in the top 4 journals during the reporting period – NEJM, Lancet, Science & Nature

10 Quarterly 3 6 3 3 2 8 2 2 19

To provide leadership in the generation of new knowledge in health

2.4*Number of ISI journal articles where the first-author is affiliated to the MRC during the reporting period

160 Quarterly 40 62 45 46 35 64 40 40 212

To facilitate the translation of MRC research findings into health policies and practices

2.5Number of new local/international policies and guidelines that reference MRC research during the reporting period

4 Annual 4 4 4

To provide funding for the conduct of health research

2.6Number of research grants awarded by the MRC during the reporting period

100 Annual 100 104 104

Support innovation and technology development to improve health

To provide funding for health research innovation and technology development

3.1Number of innovation and technology projects funded by the MRC to develop new diagnostics, devices, vaccines and therapeutics during the reporting period

30 Annual 30 34 34

Build capacity for the long-term sustainability of the country’s health

research

To enhance the long-term sustainability of health research in South Africa by providing

funding for the next generation of health researchers

4.1Number of MRC bursaries/ scholarships/ fellowships provided for post-graduate study at masters, doctoral and post-doctoral levels during the reporting period

60 Annual 60 72 72

Note: * signifies that data will be contributed by both intramural and extramural units. Where the symbol does not appear, the data is only from intramural units.

2015/16 Quarterly Targets

22

No. Programme Performance Indicator

Reporting

period

2015/16

Frequenc

y

Quarterly targets

1st 2nd 3rd 4th

1.1 Compliance with legislative prescripts, reflected in audit findings relating to the processes and systems

of the SAMRC.

Clean Annual

1.2 % of the government allocated SAMRC budget spent on administration 25 Annual

2.1 Number of published journal articles, book chapters and books by South African Medical Research

Council (SAMRC) MRC (Medical Research Council) and Medical Research Council of South Africa

(MRCSA) researchers within intramural, extramural research units and Collaborating centres at the

SAMRC (Malaria, TB, HIV and Cancer) and Self-Initiated Research , SHIP and the flagship projects

450 Quarterly 115 125 95 115

2.2 Number of published journal articles by SAMRC /MRC/MRCSA grant-holders during the reporting

period, with an acknowledgement of SAMRC /MRC/MRCSA funding support.

115 Quarterly 30 30 25 30

2.3 Number of published indexed high impact factor journal articles with an SAMRC/ MRC/MRCSA affiliated

author.

12 Quarterly 3 4 2 3

2.4 Number of journal articles where the first-author and/ or the last author is affiliated to the

SAMRC/MRC/MRCSA during the reporting period

165 Quarterly 45 45 35 40

2.5 Number of new local/international policies and guidelines that reference SAMRC research 4 Bi-Annual 2 2

2.6 Number of research grants awarded by the SAMRC 110 Annual

3.1 Number of innovation and technology projects funded by the SAMRC to develop new diagnostics,

devices, vaccines and therapeutics

30 Annual

4.1 Number of SAMRC bursaries/ scholarships/ fellowships provided for post-graduate study at masters,

doctoral and post-doctoral levels

65 Annual

GENDER & HEALTH RESEARCH UNIT

• Rachel Jewkes and her team received an ambitious grant

from DFID to address interventions to reduce gender based

violence globally

New Extramural Research Units Institution Director

Child and Adolescent Lung Health UCT Prof Heather Zar

MRC/UWC Health Services to

Systems

UWC Prof Helen Schneider

MRC/Caprisa HIV/TB Pathogenesis

and Treatment

Caprisa Prof Salim Abdool Karim

Stem Cell Research and therapy UP Prof Michael Pepper

Hypertension and Cardiovascular

Disease

NWU Prof Aletta Schutte

Antiviral Gene Therapy Wits Prof Patrick Arbuthnot

Microbial Water Quality Monitoring

Centre

UFH Prof Anthony Okoh

Herbal Drugs TUT Prof Alvaro Viljoen

MRC Cancer Research Centres Institution Director

KwaZulu-Natal Prospective Gastrointestinal

CRC

UKZN Prof Thandinkosi Madiba

MRC/UCT Gynaecological CRC UCT Prof Lynette Denny

Wits/MRC Common Epithelial CRC Wits Prof Paul Ruff

Malaria Collaborating Centres

• RFA was sent out to establish MRC collaborating centres for

malaria research

• Three centres were established

– University of Cape Town (Centre for Optimisation of Artemesinin

Therapy)

– University of Witwatersrand (Collaborating Centre for Multi-

disciplinary Research on Malaria)

– University of Pretoria (Centre for Sustainable Malaria Control)

• These centres represent centres of excellence for drug

development, Entomology and Epidemiology respectively

TB/HIV/HIV&TB Collaborating Centre Awards

COLLABORATING CENTRES

RANK Category PI OVERALL MERIT SCORE

1 TB Prof Mark Nicol 8.7

2 TB-HIV Dr Neil Martinson 8.3

3 TB-HIV Ass Prof Graeme Meintjes 8.2

4 TB Prof Adrie Steyn 8.1

5 TB-HIV Prof Gavin Churchyard 8.0

6 TB Ass Prof Mark Hatherill 7.6

7 TB-HIV Dr Ian Sanne 7.6

8 TB Prof Keertan Dheda 7.4

9 HIV Prof Wolfgang Preiser 7.2

10 HIV Prof Helen Rees 7.0

21 Applications received!

Addressing Transformation

• Ring-fenced funding for HDIs

• New model for funding early stage investigators with SIR

grants

• Twining partnerships with both local & international

universities

• Accelerating the progression of black scientists within the

SAMRC creating new associate directors

• SAMRC RFAs to tackle development as part of grant

strategy

HDI RFAInstitution PI Gender Amount

UFH Dr M Singata-Madliki F R500 000

UFH Professor E Seekoe F R500 000

R1 000 000

UL (Turf) Prof S Mathebula M R100 000

UL (Turf) Prof L Mampuru (3 projects) M R900 000

R1 000 000

Univen Prof L Netshikweta F R450 000

Univen Prof P Bessong F R550 000

R1 000 000

UNIZULU Dr AP Kappo M R1 000 000

WSU Dr W Chitha / Prof C George M/M R600 000

WSU Dr Apalata ?? R175 000

WSU Dr Banach ?? R175 000

WSU Dr C Sewani-Rusike F R50 000

R1 000 000

TOTAL R5 000 000

Submissions Success rateUL ( Turfloop) 6 project submitted (4/6)

UniVenda: 2 projects submitted (2/2)

U Zululand: 1 project submitted (1/1)

WSU: 5 projects submitted (4/5)

UFH: 2 project submitted (2/2)

HDI RFA UPDATEFunding Rationale

Non-competitive developmental grant

Budget: R5 Mil (R1 million per university for 5 years)

Selected Universities: UL (Turf), WSU, UFH, UniVen, UZ

Opening date of call: 1 April 2014

Closing date of call: 30 June 2014Institution # Applications

ARC Infruitec-Nietvoorbij 1

Cape Peninsula University of Technology 1

Council for Scientific and Industrial Research 1

Int. Centre for Genetic Engineering and Biotechnology, CT 2

Mintek 1

National Health Laboratory Service 3

Nelson Mandela Metropolitan University 9

North-West University South Africa 10

Rhodes University 5

Stellenbosch University 41

Tshwane University of Technology 2

University of Cape Town - FHS 43

University of Fort Hare 1

University of KwaZulu Natal 23

University of Limpopo (Medunsa) 3

University of Limpopo (Sovenga) 1

University of Pretoria 12

University of the Free State 2

University of the Western Cape 5

University of the Witwatersrand 31

Wits Health Consortium 3

Grand Total 200

Self Initiated Research Grants

2014 SIR guide

Research Priority Area Apps

African Traditional Medicine and Drug Discovery 12

Brain and Behavior 14

Cancer 21

Cardiovascular Disease and Metabolic Disorders 40

Environment and Health 5

Genomics and Proteomics 8

Health Systems and Policy 10

HIV & Aids 37

Infectious Disease 16

Malaria 7

Maternal, Child and Infant Health 20

Nutrition 1

Tuberculosis 9

Grand Total 200

Race Female Male Total% awards

given

African 10 18 28 53.6

Coloured 9 8 17 11.8

Indian 10 17 27 25.9

White 72 51 123 18.7

Unclassified 3 2 5

Grand Total 104 96 200

SCHOLARSHIP PROGRAMMES

Grants and Scholarships

Administration ( GSA)

1. MRC Clinician Researcher programme /PhD

value of scholarship = R500 000.00 pa

0

1

2

3

4

5

6

B W C I

Clinicians PhD programme history (21 PhD scholars)2013 -2015

M F

0

0.5

1

1.5

2

2.5

3

3.5

4

4.5

W B I C

Career Development Award history ( 16 Post docs / 4 yr funding for 2011 -15)

F M

2 . The Career Development Award (Post PhD incentive

award)

0

5

10

15

20

25

30

35

Msc PhD

3. Fifty seven SAMRC Internship programme history ( both MSc & PhD)

(2011 - March 2015)(generic black)

M F

4. (a) National Health Scholars Programme (NHSP)

PhD programme 3 year history: 2012-2015

Total of 54 Candidates

0

10

20

30

40

50

60

NHSP Cohort 1 NHSP Cohort 2 NHSP Cohort 3 Totals

Gender Representation in the 1st, 2nd and 3rd Cohorts

M F Total

13 Males

41 Females

4. (b) National Health Scholars Programme (NHSP)

PhD programme

0

5

10

15

20

25

B W C I

Race Representation in the 1st, 2nd and 3rd Cohorts

NHSP Cohort 1 NHSP Cohort 2 NHSP Cohort 3

B - 19

W - 23

C - 7

I - 6

GRANTS AND SCHOLARSHIPS

ADMINISTRATION DIVISION

Representation of SAMRC Scholarship Programmes by race, gender and or study level

1) The new National Health Scholars Programme (NHSP/PhD)2) The new MRC Clinician Researcher Programme (for MBChBs enrolled for a PhD)3) The Career Development Award (Post docs) 4) MRC/NRF Health and Allied Disciplines Scholarship Programme (MSc & PhD)5) SAMRC Internship Programme (PhD)

For more on scholarships visit: http://www.mrc.ac.za/researchdevelopment/opportunity.htm

SHIP Human Capital Development

Level Total % Black % Female

Postdoc 48 16 50

Doctoral 32 34 31

Masters 8 38 25

Technician 27 22 44

Senior Scientist 19 ? 58

TOTAL 134 21 44

New Priority areas: Mortality in Children

New Priority areas: Maternal Mortality

MCH: Current Project Portfolio

Maternal & Child Health:

• Existing projects:

– Triage Device: (CPUT) - TOMPSA

– Umbiflow: POC Placental function Doppler device

(CSIR)

– School medical record App: NMMU

• New projects in partnership with PATH

(GHIA)

– Oral Oxytocin: For post partum haemorrhage,

Eastern Cape

– Vaginal tamponade: for post partum haemorrhage

(SUN)

– Milk Banking Project: KZN

Malaria:

• Largest drug Malaria drug discovery

project in Africa

• UCT, Wits, CSIR, UP, NICD

• 100 % Matched funding by BMGF

• 1 clinical candidate,

– backup series

Malaria: Drug Discovery

• Malaria clinical candidate MMV390048 first

molecule from Africa underwent First-In-Man

(FIM) clinical trials in UCT’s new Phase I facilities

• MMV390048 – looking to head into Phase II in

2015/2016.

H3-D Malaria drug: Bench-side to Bed-side

TB:

• Multidisciplinary drug discovery project

• One of the largest TB Drug Discovery projects in the

world

UCT, Wits, K-RITH, MRC

South Africa playing a major leadership role globally

• 100% matched by BMGF

• Major collaborations facilitated with global

partners

TB: Drug Discovery

TB Current Project Portfolio

TB

• Bioinformatics

• TB Bioinformatics research Platform (MRC)

• Comprehensive Bacterial Analytical ToolKit for Tuberculosis Research

(UWC)

• Drug

• Clinical: Paediatric Levofloxacin formulation (SUN)

• Development to the Clinical Phase of Oxidant and Redox Drug

Combinations for Treatment of Malaria, TB and Related Diseases (NWU)

• Evaluating a new treatment regimen for patients with extensively drug-

resistant TB (XDR-TB) and resistance beyond XDR-TB – a randomised

controlled trial (Limpopo)

• Diagnostics:

• 4 diagnostic projects. 30 min Readout: (NWU) and UCT

• Tuberculosis Transmission: Host, Bacterium and Environment (UCT)

• Improving TB diagnosis and treatment through basic, applied and health

systems research (MRC)

HIV Current Project Portfolio

HIV

• HIV drugs:

• Targeting latent HIV reservoirs with RNA technology (Wits)

• HIV vaccines: (7 projects) NICD, Wits, UCT, CSIR

• Immunogen design: UCT, Wits

• Broadly neutralising antibodies: NICD

• Passive Immunity: NICD/Harvard

• Biopharming to produce BNAbs: CSIR

• Characterisation of breakthrough infections from HIV trials in SA: UCT

• Functional cure (biosignatures in long-term non-progressors and elite

controllers): NICD

• Platforms:

• Preclinical Research platform HIV (MRC)

• SHIV challenge model and BLT mouse model development (MRC/UCT)

HIV Current Project Portfolio

HIV

• HIV Prevention

• Silver-based microbicide: CSIR

• Diagnostics

• Vaginal inflammation diagnostic for HIV risk: UCT/CAPRISA

• HIV Resistance platform - UWC

• P5 Consortium

• Clinical Support for WSU

NCD Current Project Portfolio

Non Communicable Diseases:

• Early diabetes diagnostic (MRC)

– Blood and Urine Based

– Funding clinical validation

• Early diabetes drug (MRC)

– Comprehensive pharmacology evaluation

– Vivo support model

• Genetic/personalised medicine projects:

– Breast Cancer (SUN)

– Diabetes (UWC)

photo by U.S. Navy via Wikimedia Commons

Focus Area 2: Impact at community level

EMERGENCY

Seen immediately

VERY URGENT

Seen within 10 minutes

URGENT

Seen within 60 minutes

ROUTINE

Seen within4 hours

250,000incorrectly triaged people

Study

• Khayelitsha

– Population ca 400,000

– 8 Months study cofounded by WC DOH

– High patient volumes

• Study was major success

– Study showed an 88% reduction of mistakes

– Major reduction in waiting times

– Health Economics show radical reduction on resources

• Goal is to roll out nationally

Four initiatives from across Africa win share of global US$1 mn

healthcare innovation award

London, UK

Saturday, January 31, 2015, 12:00 Hrs [IST]

A simple mobile-phone app that helps staff at human milk banks (HMBs)

with the pasteurisation of donor breast milk and a life-saving kit for the

treatment of diarrhoea in under-fives have been awarded joint first prize in

the annual GSK and Save the Children $1 million Healthcare Innovation

Award. The University of Kwazulu-Natal (UKZN) and ColaLife Zambia

were each awarded $370,000 for their innovative approaches to helping

reduce deaths among newborns and infants.

The ‘FoneAstra’ human milk pasteurisation toolkit, originally developed by

the University of KwaZulu-Natal in collaboration with health NGO PATH

and the University of Washington, uses a mobile phone app to provide a

step-by-step guide through the pasteurisation process. The app makes it

easier to track and trace donor milk for increased quality control and

assurance and can be adapted for use in settings with no electricity. Up to

25 per cent of premature or low birth-weight babies cannot get sufficient

breast milk from their mothers, often for reasons of illness or low supply,

which leaves them more vulnerable to life threatening conditions such as

diarrhoea, pneumonia and neonatal sepsis.

Achievements 2013 - 2015

CONGRATULATIONS TO ZANDISIWE MAGWEBUZandisiwe Magwebu, an intern in the Primate Unit, has been awarded a 3-month

research internship from Novartis. The name of the program is ‘The Novartis Next

Generation Scientist Program’ and it is hosted in Basel, Switzerland. This forms part of

her PhD study, entitled ‘Hyperglycinemia in captive-bred Vervet monkeys with

cataracts: genetic dynamics and associations’.

The program is an intensive internship programfor talented and motivated research

scientists. It is a 3-month program designed to foster both their scientific and

professional development.

Achievements

3 TED Talks

DOH Strategic Projects

Ebola

NIH-MRC RFA

Non-Human Primates: Chesa Chauke

Research involving NHP played vital role in medical/scientific advances

Animal models: essential component of biomedical research

Nonhuman primates (NHP) are small component of total animal use (<

0.3%): ethical considerations

NHP are the most applicable animal model to human condition

(anatomic, physiological, genetic similarities)

NHP provide information relevant to human application

Info developed in NHP models is critical to design of human studies &

evaluation of new medical interventions into human health care

Ethical considerations are a significant factor in model selection

Among the commonly used NHP are the Rhesus (Macaca mulatta) and

the Vervet monkey (Chlorocebus aethiops)

Why Nonhuman Primate Models Matter

SAMRC PUDAC

• Maintains captive bred Vervet and Rhesus monkeys (2nd and 3rd

generation)

• Only African facility that breeds/produce captive bred African

primates for biomedical research

Services provided

• Animal care and management

• Technical and scientific support

• Research (collaborative and contract)

• Pre-clinical research and testing

• The infrastructure and capacity to maintain and utilize

primate models

• Production and administration of special diets

Vervet

Rhesus

Examples of primate use at PUDAC

Drug development: pharmacokinetics, pharmacodynamics, toxicity

Traditional medicines: toxicity and efficacy

Haematology: platelet function

Psychiatric: control of stereotyped behaviour, brain function during addiction

Reproduction: male and female contraception

Developmental: in-utero exposure

HIV/AIDS: vaccine development

Eye Diseases: cataract genetics

Cardiovascular disease: cholesterol transport, atherosclerosis

Metabolic diseases: diabetes, obesity, nonketotic hyperglycinemia(NKH)

- We have specific primate models of insulin resistance, diabetes, obesity and dyslipidaemia

SAMRC

PUDAC

INDOOR

FACILITY *

PRIMATE UNIT

(Tygerberg

)

VERVETSRODENT

S

OUTDOOR, SEMI-INDOOR FACILITY

*

DELFT ANIMAL CENTRE

(Delft)

RHESUS HORSES

FACILITIES

*Includes

theatre,

necropsy,

procedur

e rooms

and other

support

spaces

PERFORMANCE INFORMATION

2014: Top First Author Publications

68

MRC researcher:

SA Madhi (Respiratory and

Meningeal Pathogens

Research Unit)

MRC researcher:

A Von Gottberg, L de Gouveia

and SA Madhi (Respiratory and

Meningeal Pathogens Research

Unit)

MRC researcher:

C Parry and B Myers

(Alcohol, Tobacco and other

drug Research Unit)

MRC researcher:

A Stein (Rural Public Health

and Health Transition

Research Unit)

2014: Top First Author Publications

MRC researcher:

R Jewkes (Gender and Health

Research Unit)

MRC researcher:

R Matzopoulos (Burden of

disease research unit)

MRC researcher:

R Jewkes , Y Sikweyiya and N

Jama-Shai (Gender and Health

Research Unit)

69

2014 Top Altmetric Publications

MRC researcher:

AP Kengne (Non-Communicable

Diseases research unit)

MRC researcher:

AP Kengne (Non-

Communicable Diseases

research unit)

R Matzopoulos (Burden of

Disease research unit)

MRC researcher:

AP Kengne (Non-Communicable

Diseases research unit)

70

2014 Top Altmetric Publications

MRC researcher:

S Tollman (Rural Public

Health and Health Transitions

research unit)

MRC researcher:

AP Kengne (Non-

Communicable Diseases

research unit)

71

2014 Top Cited Publications

MRC researcher:

AP Kengne (Non-Communicable

Diseases research unit)

V Pillay van Wyk (Burden of

Disease Research Unit)

MRC researcher:

AP Kengne (Non-

Communicable Diseases

research unit)

72

MRC researcher:

AP Kengne (Non-Communicable

Diseases research unit)

MRC researcher:

W Hide (Bioinformatics

Capacity Development Research

unit)

2014 Top Cited Publications

73

MRC researcher:

SA Madhi, CL Cutland, L

Kuwanda, A Hugo, S Jones, PV

Adrian, N van Niekerk, KP

Klugman and MC Nunes

(Respiratory and Meningeal

Pathogens Research Unit)

MRC Act: Nkosinathi Bhuka

BACKGROUND

Since enactment in 1991, the SAMRC Act 58/1991 has never been reviewed

Three SAMRC operations reviews (SETI, ASSAf and the Revitalisation (Green

Report)

Comparison with the other statutory bodies with mandate similar to that of the

SAMRC / Institutions that the SAMRC does business with or competes with (looking

at mandate, governance, business / funding / budget model)

Out of date non-aligned with broader regulatory / public policy framework

The process of amending the SAMRC Act can be traced as far back as 10 years

47

INTENDED OUTCOME

More efficient and empowering research regulatory regime

Aligned / modernised to be in keeping with non-statutory health research best

practice and governance instruments such as the King Code on Corporate

Governance; as well as the legislation passed after it such as the National Health

Act 61of 2003, as amended, the Protection of Personal Information Act, 2013 and

the Public Finance Management Act 1of 1999, as amended.

48

FINANCIAL IMPLICATIONS

• We envisage a duration of 3 years (barest minimum +- 18 months)

• For the foreseeable minimum engagement of 18 months, our

estimation is a commitment of 5 hours a day, 2 days a week, a rate

of about R1200 per hour that places us at the region of R3 456 000

as the projected required provision for the services in the

minimum period. This does not include disbursements. We are in

the process of consulting to get a more realistic cost pricing.

49

Thank You

50